N4 Pharma (N4P) Competitors GBX 0.42 -0.03 (-7.11%) As of 08/15/2025 09:50 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsBuy This Stock N4P vs. RGT, CEL, HELD, HLN, BXP, HIK, HCM, INDV, AMYT, and AGYShould you be buying N4 Pharma stock or one of its competitors? The main competitors of N4 Pharma include Argent BioPharma (RGT), Celadon Pharmaceuticals (CEL), Hellenic Dynamics (HELD), Haleon (HLN), Beximco Pharmaceuticals (BXP), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), and Allergy Therapeutics (AGY). These companies are all part of the "drug manufacturers - specialty & generic" industry. N4 Pharma vs. Its Competitors Argent BioPharma Celadon Pharmaceuticals Hellenic Dynamics Haleon Beximco Pharmaceuticals Hikma Pharmaceuticals HUTCHMED Indivior Amryt Pharma Allergy Therapeutics Argent BioPharma (LON:RGT) and N4 Pharma (LON:N4P) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends. Which has more risk and volatility, RGT or N4P? Argent BioPharma has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, N4 Pharma has a beta of -0.37, indicating that its stock price is 137% less volatile than the S&P 500. Is RGT or N4P more profitable? Argent BioPharma has a net margin of -1,960.39% compared to N4 Pharma's net margin of -18,399.86%. Argent BioPharma's return on equity of 420.08% beat N4 Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Argent BioPharma-1,960.39% 420.08% -108.57% N4 Pharma -18,399.86%-90.68%-56.00% Which has stronger valuation and earnings, RGT or N4P? N4 Pharma has higher revenue and earnings than Argent BioPharma. N4 Pharma is trading at a lower price-to-earnings ratio than Argent BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArgent BioPharmaN/AN/A-£17.53M-£0.24N/AN4 Pharma£8.84K203.61-£1.63M-£0.35-1.21 Do institutionals and insiders believe in RGT or N4P? 1.1% of Argent BioPharma shares are owned by institutional investors. 17.8% of Argent BioPharma shares are owned by company insiders. Comparatively, 18.0% of N4 Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer RGT or N4P? In the previous week, Argent BioPharma's average media sentiment score of 0.00 equaled N4 Pharma'saverage media sentiment score. Company Overall Sentiment Argent BioPharma Neutral N4 Pharma Neutral SummaryArgent BioPharma beats N4 Pharma on 6 of the 10 factors compared between the two stocks. Get N4 Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for N4P and its competitors with MarketBeat's FREE daily newsletter. Email Address N4P vs. The Competition Export to ExcelMetricN4 PharmaDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£1.80M£2.22B£5.68B£3.09BDividend Yield3.12%2.92%3.79%5.04%P/E Ratio-1.214.2631.08174.60Price / Sales203.61614.91467.01282,733.39Price / Cash2.2510.3737.4027.94Price / Book0.9311.109.095.38Net Income-£1.63M£20.70B£3.26B£5.89B7 Day Performance-16.40%2.59%7.36%-0.13%1 Month Performance5.03%5.91%5.47%1.01%1 Year Performance-16.40%3.40%30.61%64.41% N4 Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)N4PN4 PharmaN/AGBX 0.42-7.1%N/A-24.7%£1.80M£8.84K-1.215Gap DownRGTArgent BioPharmaN/AN/AN/AN/A£8.31MN/A-0.65N/AGap DownHigh Trading VolumeCELCeladon PharmaceuticalsN/AGBX 13.40flatN/AN/A£8.22M£123.38K-1.682,780HELDHellenic DynamicsN/AGBX 0.01flatN/AN/A£14KN/A0.00N/AHLNHaleon1.3571 of 5 starsGBX 355.20+0.6%GBX 413.50+16.4%-5.0%£32.06B£11.07B29.8725,408BXPBeximco PharmaceuticalsN/AGBX 44.50flatN/A+36.6%£30.33B£7.08T4.775,500Gap UpHIKHikma Pharmaceuticals4.0208 of 5 starsGBX 1,729.97-1.1%GBX 2,553.33+47.6%-13.0%£4.80B£3.74B16.989,100Analyst ForecastHCMHUTCHMEDN/AGBX 221.01-10.0%N/A-20.1%£2.40B£771.01M-56.411,760Gap UpHigh Trading VolumeINDVIndivior2.4733 of 5 starsGBX 1,238+1.6%GBX 1,650+33.3%+28.1%£1.93B£1.40B-1,026.481,000Gap UpHigh Trading VolumeAMYTAmryt PharmaN/AN/AN/AN/A£457.11M£210.24M-4.33290Gap DownAGYAllergy TherapeuticsN/AGBX 8.75+2.9%N/A+63.0%£430.07M£72.18M-8.43612Gap Down Related Companies and Tools Related Companies Argent BioPharma Alternatives Celadon Pharmaceuticals Alternatives Hellenic Dynamics Alternatives Haleon Alternatives Beximco Pharmaceuticals Alternatives Hikma Pharmaceuticals Alternatives HUTCHMED Alternatives Indivior Alternatives Amryt Pharma Alternatives Allergy Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:N4P) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding N4 Pharma Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share N4 Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access